

Rolando Pajon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10035750/publications.pdf>

Version: 2024-02-01

13
papers

11,222
citations

686830

13
h-index

1125271

13
g-index

17
all docs

17
docs citations

17
times ranked

17704
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. <i>New England Journal of Medicine</i> , 2021, 384, 403-416.	13.9	7,910
2	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> , 2022, 375, 43-50.	6.0	788
3	Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. <i>Science</i> , 2021, 373, 1372-1377.	6.0	459
4	Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. <i>New England Journal of Medicine</i> , 2021, 385, 1774-1785.	13.9	402
5	Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. <i>Nature Medicine</i> , 2021, 27, 2025-2031.	15.2	361
6	SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. <i>New England Journal of Medicine</i> , 2022, 386, 1088-1091.	13.9	338
7	Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. <i>New England Journal of Medicine</i> , 2021, 385, 2241-2251.	13.9	267
8	Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351. <i>New England Journal of Medicine</i> , 2021, 384, 2352-2354.	13.9	202
9	A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. <i>Vaccine</i> , 2021, 39, 2791-2799.	1.7	185
10	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> , 2021, , eab3435.	6.0	145
11	Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. <i>Nature Medicine</i> , 2022, 28, 1042-1049.	15.2	61
12	Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge. <i>New England Journal of Medicine</i> , 2021, 385, 2485-2487.	13.9	49
13	Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial. <i>Nature Medicine</i> , 2022, 28, 823-830.	15.2	26